Xenon Pharmaceuticals Inc.(XENE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Xenon Pharmaceuticals Inc. (XENE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XENE at 24.0/100 on a 32-signal composite quality model, placing it at rank #2,804 of 3,064 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (2.3) and institutional flow (16.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Xenon Pharmaceuticals Inc. reports net income of $-110.7M, free cash flow of $-95.7M. Top institutional holders of XENE by reported 13-F value include FMR, BlackRock, Avoro Capital Advisors, based on the most recent SEC filings. XENE trades on the Nasdaq exchange and files with the SEC under CIK 1582313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XENE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xenon Pharmaceuticals Inc. directly from SEC EDGAR.